

Global Access Program Providing innovative diagnostics solutions to those who need it most



Universal access to quality healthcare and medical innovation remains a global challenge.

As a community we have an ambitious goal: to stop as many diseases as possible.

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies to go beyond providing diagnostics tests.







S The Global Fund

The Roche Global Access Program provides access to diagnostics for HIV, hepatitis, tuberculosis and cervical cancer in high disease burden and qualified countries where reliable diagnostic solutions are needed most.



- Global Access Program Timeline

2014 Announced Global Access Program for HIV viral load testing

2018 Launch of **cobas**[®] simplify sample collection and transportation and increase access to HIV monitoring testing

2021 Expansion of the Global Access Program to include molecular PCR diagnostic tests for COVID-19

2016-2017

Expansion to include Early Infant Diagnosis and additional **cobas**[®] Systems family

2019 Expansion of the Global Access Program to include access to diagnostics for tuberculosis, hepatitis, and cervical cancer

DISEASE PREVALENCE: DEATHS

HIV

In 2018, approximately **770,000** people died due to HIV.¹

Нер

In 2015, hepatitis B resulted in an estimated **887,000** deaths. In 2016, approximately

399,000 people died from hepatitis C.²

HPV

In 2018, more than **300,000** women died of cervical cancer, more than 85% of these deaths occurring in low- and middleincome countries.⁴ COVID-19

In 2020, COVID-19 caused more than **1.8 million** deaths globally.⁹

DISEASE ELIMINATION GOALS

HIV goals by 2030⁵

ТΒ

In 2018,

1.5 million died

from the disease.3

95%

of people living with HIV will know their HIV status



of people who know their status receive treatment



of treatment on HIV treatment have a suppressed viral load

Hepatitis goals by 2030[°]



reduction in new cases of chronic hepatitis B and C



reduction in hepatitis B and C



of treatment eligible persons with chronic hepatitis B and C infections

TB goals by 2030⁷



reduction in the absolute number of TB deaths



reduction in the TB incidence rate




of TB-affected households experiencing catastrophic costs due to TB

Cervical cancer goals by 2030[®]



of girls fully vaccinated with HPV vaccine by 15 years



of women HPV screened at 35 and 45 years of age and all



of women identified with cervical disease receive treatment for

precancerous lesions or invasive cancer

COVID-19 Elimination Strategy⁷



Increase diagnostic testing for disease surveillance and to prevent initial spread


implement physical distancing measures to decrease rates of transmission



increase awareness, education, and access to vaccinations

COUNTRIES WITH GLOBAL ACCESS PROGRAM

The program provides increased access to diagnostics at affordable pricing for qualifying organizations in 82 eligible countries with the highest disease burden.



REFERENCES:

- 1. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (accessed 7 Nov 2019)
- https://www.who.int/news-room/fact-sheets/detail/hepatitis-b and https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed 7 Nov 2019)
- 3. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (accessed 7 Nov 2019)
- 4. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer (accessed 7 Nov 2019)
- Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030. https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf (Accessed 29 March 2021)
- 6. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1 (accessed 7 Nov 2019)
- 7. The End TB Strategy 2015. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.19
- 8. https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf (accessed 7 Nov 2019)
- 9. https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality. Accessed 28June2021

10. Baker MG, Wilson N, Anglemyer A. Successful Elimination of Covid-19 Transmission in New Zealand. N Engl J Med 2020;383:e56. 10.1056/NEJMc2025203

Roche Molecular Systems 4300 Hacienda Drive Pleasanton, CA 94588 USA

https://go.roche.com/Global-Access-Program